Efficacy and safety of rimegepant in Chinese women with pure menstrual migraine: a retrospective observational study. [PDF]
BMC NeurolYe W +7 more
europepmc +1 more source
Optimisation or Restriction? Unpacking the Logic Behind NICE Decisions. [PDF]
PharmacoeconomicsHenderson N +3 more
europepmc +1 more source
Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial. [PDF]
PLoS OneFranjic D +4 more
europepmc +1 more source
Retrospective analysis of the tolerability and effectiveness of rimegepant for the acute treatment of migraine in adolescents. [PDF]
HeadacheTourlas K +4 more
europepmc +1 more source
Integrating gepants into clinical practice for the acute treatment of migraine. [PDF]
HeadacheLipton RB +4 more
europepmc +1 more source
Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data. [PDF]
HeadacheGiacon M, Terrazzino S.
europepmc +1 more source
RIMEGEPANT REVIEW: ANALYTICAL PROFILE AND NEW DEVELOPMENTS
ABSTRACTIn order to measure Rimegepant (Nurtec ODT/Vydura) and evaluate its stability in bulk andtablet forms, this review summarizes validated RP-HPLC and LC-MS/MS analyticaltechniques. Using mobile phases of organic-aqueous mixtures, pH 7.0 phosphate buffers, oracidified systems with UV/PDA detection at 260–280 nm, chromatographic separations ...
openaire +1 more source
Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo-controlled clinical trials. [PDF]
HeadacheCharleston L +6 more
europepmc +1 more source
Neurotransmitter modulation: a roadmap to precision neuro-immune oncology. [PDF]
Signal Transduct Target TherBillingsley JL, Bhunnoo S, Benoit YD.
europepmc +1 more source